

ASH 2023

65th ASH Annual Meeting and Exposition

December 9–12, 2023
San Diego, US



 **MultipleMyelomaHub**

TOP ABSTRACTS

To help navigate the exciting content being presented at the 65th ASH Annual Meeting and Exposition, we have provided recommendations for the top abstracts to look out for in multiple myeloma.

ASH 2023: Top abstracts in MM

December 9–12, 2023

Newly diagnosed multiple myeloma		
Abstract	Title	
4 View	Results of the phase III randomized Iskia trial: Isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients	Francesca Gay
207 View	Daratumumab, carfilzomib, lenalidomide, and dexamethasone induction and consolidation with tandem transplant in high-risk newly diagnosed myeloma patients: Final results of the phase 2 study IFM 2018-04	Cyrille Touzeau
208 View	Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed MM: First results of the phase 2 EMN26 study	Niels W.C.J. van de Donk
209 View	GEM2017FIT trial: Induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) Plus/minus daratumumab (D), 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: Phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma (NDMM) Patients aged between 65 and 80 years	Maria-Victoria Mateos
339 View	Minimally invasive assessment of measurable residual disease (MRD) in multiple myeloma (MM)	Carmen Gonzalez
340 View	Mass spectrometry-based assessment of M-Protein in peripheral blood during maintenance therapy in multiple myeloma (MM) in the phase III ATLAS trial	Tadeusz Kubicki
342 View	Dynamic frailty status enables better prediction of survival probability - results of the HOVON 143 study	Febe Smits
533 View	Longitudinal screening of mutant hematopoietic progenitor cells (HPC) in multiple myeloma (MM) and its association with secondary primary malignancies (SPM)	Cristina Perez
647 View	Comparison of response and survival outcomes in standard- and high-risk newly diagnosed transplant-eligible multiple myeloma (NDMM) patients treated with lenalidomide, bortezomib and dexamethasone (RVD) versus daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD)	Nisha S. Joseph
1022 View	Updated results of a phase I open-label single-arm study of dual targeting BCMA and CD19 fastcar-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma	Juan Du

4762 View	Treatment outcomes and prognostic factors with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus rvd plus autologous stem cell transplantation (ASCT) in African American (AA) patients (Pts) with newly diagnosed multiple myeloma (NDMM) in the determination phase 3 trial	Jeffrey A. Zonder
LBA-1 View	Phase 3 randomized study of daratumumab (DARA) + bortezomib, lenalidomide, and dexamethasone (VRd) versus Vrd alone in patients (Pts) with Newly diagnosed multiple myeloma (NDMM) Who are eligible for autologous stem cell transplantation (ASCT): Primary results of the Perseus trial	Pieter Sonneveld

Relapsed and/or refractory multiple myeloma

Abstract	Title	
91 View	Real-world safety and efficacy of teclistamab for patients with heavily pretreated relapsed-refractory multiple myeloma	Danai Dima
219 View	BMS-986393 (CC-95266), a G protein–coupled receptor class C group 5 member D (GPRC5D)–targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Updated results from a phase 1 study	Susan Bal
338 View	Venetoclax in combination with daratumumab and dexamethasone elicits deep, durable responses in patients with t(11;14) relapsed/refractory multiple myeloma: Updated analyses of minimal residual disease negativity in phase 1/2 study	Nizar J. Bahlis
761 View	Efficacy outcomes and characteristics of patients with multiple myeloma (MM) Who achieved sustained minimal residual disease negativity after treatment with equecabtogene autoleucel (Eque-cel, CT103A) in Fumanba-1	Chunrui Li
783 View	Ixazomib-based consolidation and maintenance prolongs progression-free survival after salvage autologous stem cell transplantation (sASCT): Results from interim analysis of UK-MRA Myeloma XII (ACCoRD)	Gordon Cook
1009 View	Randomized phase 3 study of pomalidomide cyclophosphamide dexamethasone (PCD) Versus pomalidomide dexamethasone (PD) in relapse or refractory myeloma: An Asian Myeloma Network (AMN) study	Wee-Joo Chng
1010 View	Efficacy and safety of less frequent/lower intensity dosing of talquetamab in patients with relapsed/refractory multiple myeloma: Results from the phase 1/2 MonumentAL-1 study	Ajai Chari
1011 View	Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose	Hang Quach
1013 View	Mezigdomide (MEZI) plus dexamethasone (DEX) and daratumumab (DARA) or elotuzumab (ELO) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Results from the CC-92480-MM-002 trial	Paul G. Richardson

1014 View	Talquetamab + pomalidomide in patients with relapsed/refractory multiple myeloma: Safety and preliminary efficacy results from the phase 1b MonumentAL-2 study	Jeffrey V. Matous
1021 View	The phase 2 CARTITUDE-2 trial: Updated efficacy and safety of ciltacabtagene autoleucel in patients with multiple myeloma and 1-3 prior lines of therapy (cohort A) and with early relapse after first line treatment (cohort B)	Jens Hilengrass
1027 View	Real world outcomes with idecabtagene vicleucel (Ide-Cel) CAR-T cell therapy for relapsed/refractory multiple myeloma	Surbhi Sidana
1028 View	Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class exposed (TCE) relapsed and refractory multiple myeloma (RRMM): Updated analysis from KarMMa-3	Paula Rodríguez Otero
3377 View	Updated results of talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma with prior exposure to t-cell redirecting therapies: Results of the phase 1/2 MonumentAL-1 study	Andrzej J. Jakubowiak
3499 View	Alternative Lymphodepletion strategies lead to similar response rates and toxicities in standard-of-care BCMA-directed CAR-T therapy in relapsed refractory multiple myeloma	Shonali Midha

Other plasma cell dyscrasias

Abstract	Title	
210 View	Efficacy and safety of daratumumab (DARA) monotherapy in patients with intermediate-risk or high-risk smoldering multiple myeloma (SMM): Final analysis of the phase 2 Centaurus study	Ola Landgren
530 View	Predicting an underlying clonal plasma cell population in light-chain monoclonal gammopathy of undetermined significance using free light-chain ratio	Jon Thorir Oskarsson
539 View	Efficacy and safety of daratumumab monotherapy in newly diagnosed patients with stage 3B light-chain amyloidosis: A phase 2 study by the European Myeloma Network	Efstathios Kastritis
542 View	Real-world treatment patterns and clinical outcomes among triple-class exposed and b-cell maturation antigen (BCMA) exposed multiple myeloma patients	Hira Mian
645 View	Isolated and dynamic peripheral blood residual disease status characterized by mass spectrometry predicts outcome in patients with high risk smoldering multiple myeloma treated in the GEM-CESAR trial	Noemi Puig
754 View	Exploiting the gut microbiota to boost immunotherapy and switch the trajectory of multiple myeloma	Laura Lucia Cogrossi

ASH 2023: Top abstracts by region

In addition to the top abstracts selected by our steering committee, the Multiple Myeloma Hub would like to highlight some key region-specific abstracts in the field of multiple myeloma and plasma cell dyscrasias.

LATIN AMERICA		
Abstract	Title	
3346 View	Renal Failure in Patients with Newly Diagnosed Multiple Myeloma Eligible for Autologous Stem Cell Transplant in LATAM - on behalf of Gelamm	Humberto Martinez-Cordero
3352 View	Survival of patients with multiple myeloma treated with bortezomib-based triplets and autologous hematopoietic stem cell transplant as first line in Latin America	Eloisa Riva

ASIA PACIFIC		
Abstract	Title	
3325 View	Impact of 1q21 gain and amplification on daratumumab-treated multiple myeloma patients: Real-world data from the Australia-New Zealand and Asia-Pacific myeloma and related diseases registries	Kenneth J C Lim
2019 View	Isatuximab rescue for inadequate response to lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: Primary analysis of the phase II Iril study of the Australian Myeloma Research Consortium (AMaRC 18-02)	Slavisa Ninkovic
2225 View	Comparison of various stem cell mobilization regimens for multiple myeloma: A 15-year retrospective institutional analysis from India	Sumeet Mirgh
4845 View	Three-year follow-up on efficacy and safety results from phase 1 Lummicar study 1 of zevorcabtagene autoleucel in Chinese patients with relapsed or refractory multiple myeloma	Chengcheng Fu

EUROPE, THE MIDDLE EAST AND AFRICA

Abstract	Title	
1981 View	Update analysis of central nervous system multiple myeloma prognosis and survival: A real-world multi-institutional study of the Greek Myeloma Study Group	Eirini Katodritou
2020 View	Low-dose venetoclax-dexamethasone in t(11;14) positive relapsed and refractory multiple myeloma; interim results from the ongoing, Danish, investigator-initiated, open label, phase 2 Victoria study	Agoston Gyula Szabo
4696 View	Risk of Infections in multiple myeloma in the era of novel agents, a population-based study based on 8672 multiple myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry	Cecilie Hveding Blimark
4729 View	Upfront autologous stem cell transplantation in myeloma patients >65 years: A population-based study from the Nordic Myeloma Study Group	Kari Lenita Falck Moore
4734 View	Bortezomib-cyclophosphamide-dexamethasone (VCD) vs bortezomib-lenalidomide-dexamethasone (VRD) in newly diagnosed multiple myeloma: A matched real-world analysis from the Balkan Myeloma Study Group (BMSG)	Efstathios Kastritis
4973 View	Autologous stem cell transplantation for multiple myeloma in Algeria	Malek Benakli



ASH 2023

Follow us on X to keep up to date with the latest from the congress

@MM_Hub

#ASH23

View all @MM_Hub tweets from #ASH23

 **MultipleMyelomaHub**

Brought to you by



**Scientific
Education
Support**